Conclusions Major ECG abnormalities are common among childhood cancer survivors, associated with increasing doses of anthracyclines and cardiac radiation, and predictive of both cardiac and all-cause mortality. (Am Heart J 2017;189: 19-27.) Cardiovascular complications of cancer therapy can hinder active treatment and contribute to late morbidity and mortality among survivors. Traditional cytotoxic agents as well as newer immune-based therapies have acute and chronic cardiac effects. 1 Anthracycline-induced heart failure has been the most studied and resulted in recommendations for echocardiographic surveillance from both cardiology and oncology professional societies. 2 However, cardiac effects of cancer therapy may also include coronary artery disease, valvular dysfunction, pericardial complications, or rhythm and conduction disturbances, 3, 4 which may not be adequately evaluated by traditional echocardiography.
Although evidence for routine electrocardiographic (ECG) screening in the asymptomatic general population is mixed, 5 cardiovascular monitoring frequently begins with an ECG. Numerous population-based studies suggest that ECG abnormalities are prevalent and predictive of incident cardiovascular events. 6 Cardiovascular surveillance has become increasingly important for cancer survivors, and efforts to improve early identification of cardiotoxicity advocate for newer, more advanced imaging modalities such as cardiac magnetic resonance imaging and tissue Doppler imaging. [7] [8] [9] However, no studies have systematically assessed ECG abnormalities among cancer survivors, leaving the role of ECG monitoring in this population poorly defined.
Cardiovascular disease is the leading noncancer cause of death among children cured of cancer, 10 and follow-up guidelines recommend baseline ECG testing followed by echocardiography based upon treatment and age at exposure. 11 Arrhythmias have been reported in small cohorts 12, 13 or single diagnostic groups, 14 but a detailed investigation of rhythm disturbances is lacking. Some have suggested nominal yield from ECG testing, but these evaluations were limited to cardiotoxic-exposed survivors, potentially missing abnormalities among those with other exposures. 15 Using the St Jude Lifetime Cohort (SJLIFE), 16, 17 an ongoing study evaluating health outcomes among adults previously treated for a pediatric malignancy, we systematically assessed ECG findings irrespective of treatment exposures. The aim of this investigation was to determine the occurrence of and risk factors for ECG abnormalities and associations between abnormalities and mortality among adult survivors of childhood cancer.
Methods

Participants
Among 4,153 eligible cancer survivors (≥18 years old and ≥10 years from diagnosis) treated for a malignancy at St Jude Children's Research Hospital, 2,715 (65%) returned for a comprehensive health evaluation, including a standard 12-lead resting ECG between November 1, 2007, and June 30, 2014 . Two hundred twenty-one were lost to follow-up, 251 elected to participate by survey only, 375 declined, 458 were pending contact/scheduling, and 133 were missing either ECG (n = 47) or radiation dosimetry (n = 86) (Supplemental Figure) . A control group, frequency matched on age, sex, and race/ ethnicity, was randomly and concurrently recruited from friends and non-first-degree relatives of current and former St Jude patients (ie, individuals who might be accompanying or visiting a patient), minimizing the chance of close relatives of SJLIFE participants being a control participant. Documents and procedures were approved by the institutional review board; all participants provided informed consent.
Major and minor ECG abnormalities
Primary outcomes were major and minor ECG abnormalities classified by the Minnesota Code. 18 Recordings were obtained (MAC1200; GE Healthcare, Milwaukee, WI) following a 5-minute rest, electronically stored, and digitally transferred to the Epidemiological Cardiology Research Center (Wake Forest University School of Medicine, Winston-Salem, NC) for central review and coding. Major ECG abnormalities included major ventricular conduction defects (complete left or right bundlebranch block, major ventricular conduction delay with QRS N120 milliseconds), definite myocardial infarction (defined as the presence of major Q wave abnormalities), possible myocardial infarction (defined as the presence of minor Q/QS wave plus major ST/T abnormalities), isolated major ST/T wave abnormalities, left ventricular hypertrophy with strain pattern, advanced atrioventricular conduction abnormalities (complete or second-degree AV block), pacemaker, atrial fibrillation/flutter, and others. The QT interval was calculated with the QT index, which accounts for the distribution of QTc in the general population. 19 Minor ECG abnormalities included minor isolated Q/QS wave abnormalities, minor isolated ST/T wave abnormalities, high R waves/increased QRS voltage denoting left or right ventricular hypertrophy without strain pattern, nonischemic ST-segment elevation, incomplete (left or right) bundle-branch block, short PR interval, left axis deviation, right axis deviation, atrial and ventricular premature beats, atrial enlargement, and others. Participants with only minor ECG abnormalities were classified as having "any minor abnormalities," and participants with major ECG abnormalities with or without coexisting minor ECG abnormalities were classified as having "any major ECG abnormalities".
Mortality
Mortality was ascertained using a combination of the National Death Index search (through December 31, 2013) and the St Jude Children's Research Hospital Cancer Registry (continuous process). Cause of death was identified using International Classification of Diseases, Ninth and 10th Revision, codes from the National Death Index or direct review of death certificates, medical records, or next-of-kin interviews conducted by registry staff. (Causes of death are shown in Supplemental Table I ).
Other variables
Sociodemographic information, including age, sex, race, and smoking status, was obtained from questionnaires.
Smoking was classified as current, past, or never, with those who reported smoking at least 100 cigarettes, but not in the last month, categorized as past smokers. Body mass index was calculated by dividing weight by height squared (kg/m 2 ) and classified as underweight (b18.5 kg/m 2 ), normal (18.5-24.9 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), and obese (≥30.0 kg/m 2 ). Dyslipidemia was defined as a fasting low-density lipoprotein cholesterol ≥160 mg/dL, high-density lipoprotein cholesterol b40 mg/dL (men) or b50 mg/dL (women), triglycerides N150 mg/dL, or on treatment for a lipid abnormality. Diabetes was defined as a fasting blood glucose ≥126 mg/dL, hemoglobin A1C ≥6.5%, or on an oral antihyperglycemic agent or insulin. Hypertension was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or taking an antihypertensive medication.
For cancer survivors, diagnosis and treatment information were obtained from medical records. Mean radiation dose to the heart in centigray (cGy) (including scatter doses) was determined by radiation physicists at MD Anderson Cancer Center (Houston, TX) using energy source, tumor dose, and field location. 20 Cumulative anthracycline (doxorubicin equivalents) and alkylating agent (cyclophosphamide equivalents) doses were calculated in milligrams per square meter (mg/m 2 ).
21,22.
Statistics
Descriptive statistics were used to characterize participants, nonparticipants, and controls and compared using χ 2 statistics or 2-sample t tests as appropriate. The prevalence (percentages and 95% CIs) of major and minor ECG abnormalities was calculated overall and by cancer diagnosis and treatment exposures. We had N90% power to detect a difference between the 2 proportions using a 2-sided, 2-sample binomial test with an α level of .05. Multivariable logistic regression was used to evaluate associations between demographic characteristics, lifestyle variables, and treatment exposures and major or minor ECG abnormalities. Variables with P values ≤ .2 on univariate analysis were retained in final models. Cox proportional hazards regression was used to evaluate associations between ECG abnormalities and risk of death and cardiovascular events. SAS version 9.3 was used for all analyses, and P values b .05 were considered statistically significant.
The SJLIFE Study is funded by the National Cancer Institute grants U01 CA195547 and CA21765 and the American Lebanese Syrian Associated Charities. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.
Results
Participating survivors differed from nonparticipants by sex (P b .01) (Supplemental Table II (Table I) . Nearly a third (29.5%) of survivors had received cardiac-directed radiation, and 57.9% and 60% were exposed to anthracycline and/or alkylating chemotherapies, respectively. Survivors and controls did not differ on traditional cardiovascular risk factors such as body habitus, smoking, hypertension, diabetes, or dyslipidemia. Pertinent chronic health conditions, graded per a modified version of the National Cancer Institute's Common Terminology Criteria for Adverse Events, 17 and the distribution of cardiovascular medications used in the cohort are provided in Supplemental Tables III and IV. A major ECG abnormality was identified in 10.7% (290 of 2,715) of survivors compared with 4.9% (13 of 268) of controls (P b .001, Table II ). The most common abnormalities among survivors were isolated major ST/T wave abnormalities (7.2%), evidence of definite or probable myocardial infarction (3.7%), and left ventricular hypertrophy with strain pattern (2.8%). These findings were asymptomatic, with the exception of 4 of 99 survivors with pathologic Q waves who reported knowledge of a prior myocardial infarction. The prevalence of minor ECG abnormalities was similar between survivors (65.2%) and controls (67.5%).
Abnormalities were identified across all treatment exposures ( Figure 1 ). The prevalence of major abnormalit ies was hi ghest among tho se exp os ed t o cardiac-directed radiation but also substantial among those treated with chemotherapy only. Among those treated with anthracyclines and/or alkylating agents alone, 8.5% and 6.8%, respectively, had a major abnormality. This increased to 17.3% and 23.2% for those treated with these agents and cardiac-directed radiation. Even among survivors not exposed to cardiotoxic therapies (ie, radiation, anthracyclines, alkylating agents) 6.5% had a major abnormality. Table III shows the odds for major or minor ECG abnormalities among cancer survivors as a function of demographic characteristics, lifestyle factors, and treatment exposures. Anthracycline exposure ≥300 mg/m 2 , increasing doses of cardiac radiation, and hypertension were associated with having a major ECG abnormality. Cardiac radiation, hypertension, and male sex were associated with having a minor ECG abnormality. Cardiac radiation doses ≥3,000 cGy conferred the greatest odds for either a major or minor ECG abnormality.
Eighty of the 2,715 (2.9%) survivors died a median of 20 months (3-87) after the initial ECG (a median of 34 years, range 13-48 years from initial cancer diagnosis). Thirteen of the 80 deaths were cardiac related (Supplemental Table I ). Adjusting for age at diagnosis, current age, gender, race, and smoking, the risk of death was elevated for survivors with a major abnormality (hazard ratio 4.0, 95% CI 2.1-7.8) ( Table IV) . The cumulative incidence of death is shown in Figure 2 . At 60 months, 10% (95% CI 6.1-13.7) of survivors with a major abnormality had died.
Discussion
In this large well-characterized cohort of adults previously treated for childhood cancer, we identified a major ECG abnormality in N10% of survivors. Cancer survivors had twice the prevalence of major abnormalities compared with controls, and abnormalities were strongly associated with cardiac radiation and higher anthracycline and alkylating chemotherapy exposures. Importantly, major abnormalities appear to predict cardiovascular events and/or all-cause death. These findings add to a sparse literature concerning rhythm abnormalities following cancer therapy. Larsen et al 13 studied a young adult population of survivors (n = 134) a mean of 5 ± 4 years after cardiotoxic exposure and reported the majority of ECGs (66%) to have no abnormalities. However, significant findings included 14% with a prolonged QTc (N0.44 second), 6% with ectopic atrial rhythms, and abnormally flattened or inverted T waves in 2%. Similarly, Schwartz et al 23 reviewed ECGs among cardiotoxic-exposed survivors returning for follow-up surveillance (n = 52). Among Abnormalities are not mutually exclusive; participants may have had more than 1 abnormality. ⁎ Among 2425 survivors and 255 controls without major abnormalities. † Reasons for pacemaker placement: complete atrioventricular block (n = 5), Wolff-Parkinson-White syndrome (n = 1), Sick sinus syndrome (n = 1), dilated cardiomyopathy (n = 1), ventricular asystole s/p aortic valve replacement (n = 1).
those exposed to b300 mg/m 2 of anthracyclines, 16% (3 of 19) had a QTc interval ≥0.43 second, with 58% (19 of 33) exposed to higher doses having a prolonged QTc. These investigators also performed exercise ECG testing in a subpopulation of 8 survivors. Only 2 responded with normal shortening of the QTc; the remaining 6 had further prolongation with exercise, raising concern for a possible abnormal neural response. Our study included a broader population further from exposure and found a low prevalence of QTc prolongation (2.2%). Furthermore, we used the QT index that accounts for the distribution of QTc in the general population, 19 whereas previous investigations have used the Bazett formula to define QTc prolongation, known to overestimate this interval. 24 A number of large cohort studies have identified associations between ECG abnormalities and future cardiovascular events. Framingham investigators reported ST/T wave abnormalities among 8.5% of men and 7.7% of women aged 44-74 years old, 25 similar to the prevalence of major ST/T wave abnormalities (7.2%) in our population. With N30 years of follow-up, Framingham researchers identified an association between ST/T wave abnormalities and incident coronary disease independent of known cardiovascular risk factors. Among 1,673 men, aged 40-55 years, participating in the Chicago Western Electric Study, 26 the risk for all-cause death was 1.6 (95% CI 1.0-2.4) among those with persistent ST/T wave abnormalities compared with those without. Although not restricted solely to ST/T wave abnormalities, cancer survivors with a major abnormality were significantly more likely to die compared with those with a minor or no abnormality. Further follow-up will help characterize this group of cancer survivors, with the goal of better informing screening frequencies and defining appropriate screening modalities.
In addition to ST/T wave abnormalities, we identified Q waves (3.7% pathologic and 7.4% minor isolated Q/QS waves) suggestive of myocardial injury/ischemia. In the general population, the prevalence of silent myocardial infarction identified by ECG ranges from 0.3% to 6.4% and is largely influenced by age. 27 In the Reykjavik Study (n = 9,141 men), the prevalence at age 50 years was 0.5% and increased to 5% by age 75 years. 28 In an older population (mean age 62 years), investigators in Olmsted County, Minnesota, reported unrecognized myocardial infarction in 3.9%, 29 similar to the prevalence of major Q wave findings in our much younger cohort. Because the prognosis following silent myocardial infarction does not differ from that of acute myocardial infarction, these findings have important implications for the future health of survivors of childhood cancer.
Electrocardiographic estimates of left ventricular hypertrophy (LVH) with the strain pattern (ST segment depression and flat or negative T waves) 30 are estimated at 0.8% among men and 0.5% among women. [30] [31] [32] The prevalence was higher (2.8%) in our population of cancer survivors. Importantly, these ECG findings have been associated with an increased risk of myocardial infarction, heart failure, and cardiovascular death. 33 Although LVH is associated with hypertension, Framingham investigators reported that a strain pattern is also predictive of hypertension and identifies hypertensive patients with decreased coronary circulation at risk of Prevalence of major ECG abnormalities by cancer treatment exposure. myocardial damage. 33 In childhood cancer survivors, risks for adverse cardiac outcomes are substantially higher in the presence of traditional cardiovascular risk factors, perhaps suggesting an increased susceptibility to conditions of aging. Hypertension may particularly potentiate the therapy-associated risks for coronary disease (relative risk [RR] 6.1, 95% CI 3.4-11.2), heart failure (RR 19.4, 95% CI 11.4-33.1), and arrhythmia (RR 6.0, 95% CI 1.7-21.8) in this population. 34 Electrocardiographic LVH with strain pattern may augment echocardiographic findings in a cancer population at high risk for cardiomyopathy.
Cardiovascular screening following cancer therapy has typically focused on ultrasound imaging and assessment of those exposed to known cardiotoxic therapies, such as anthracyclines and/or cardiac-directed radiation. By systematically obtaining ECGs on all survivors in the SJLIFE cohort, we identified abnormalities among those with and without typical cardiotoxic exposures. Even individuals not treated with cardiotoxic therapies had ECG abnormalities (6.5% major), perhaps reflective of the general population but potentially related to prior cancer therapy. Furthermore, many of the findings were suggestive of ischemic heart disease, perhaps expected among irradiated survivors but less so among those exposed to chemotherapy only. Ischemic disease may not be fully evaluated by echocardiography, thus, missing an opportunity to clinically intervene or provide health counseling. It is possible that current screening parameters underestimate the risk among cancer survivors and a broader cardiac assessment is needed.
In the general population, cardiovascular screening of asymptomatic individuals typically relies on stratification to low-, intermediate-, or high-risk categories (eg, Framingham Risk Score) to guide the most appropriate screening modalities. In a systematic review, the US Preventive Cumulative incidence of all-cause death. Services Task Force found resting ECG abnormalities to be associated with increased risk for cardiovascular events and suggested considering screening for those at intermediate or high risk. 5 Because adult survivors of childhood cancer have added risks related to treatment exposures, determining who to screen and when based on traditional risk calculators is challenging. 3 Screening modalities may need to be more carefully tailored, and ECG, a noninvasive, inexpensive modality, may provide an initial broad cardiovascular assessment, augment echocardiographic data, and guide the use of other screening modalities among these at-risk individuals.
A number of limitations should be considered when interpreting our results. Participation required an on-campus evaluation to obtain an ECG recording. Excluding survivors who may not have been able to travel because of commitments, illness, or death potentially may have affected our findings. Among those who did participate, ECGs were unavailable for 47 survivors because of technical reasons such as suboptimal recording, poor electrical transmission, and others. We assumed the missing to be noninformative and treated these data as missing at random. False-positive ECG findings may have led to misclassification bias.
Optimal strategies for cardiovascular risk assessment remain a focus of research and debate within the cardiovascular community, 35 as well as among health care providers caring for cancer survivors. Guidelines developed for the long-term follow-up of childhood cancer survivors suggest a baseline ECG, largely for the purpose of evaluating the QTc interval, but surveillance remains largely focused on echocardiographic imaging. 36 These data suggest that ECG evaluation may be more informative than previously recognized. Major ECG abnormalities were predictive of adverse outcomes, identifying a population that may warrant earlier and more comprehensive cardiac assessment and intervention. In addition, long-term follow-up of minor ECG abnormalities is needed to elucidate the natural progression within this high-risk population.
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ahj.2017.03.023.
